Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma

BMC Cancer

Table 3 Adverse events in the two groups

Event	IC* (n = 98)		IC + immunotherapy (n = 65)		p^#
Event	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4
Anorexia	57 (58.2%)	0	40 (61.5%)	0
Nausea	40 (40.8%)	0	24 (36.9%)	0
Fatigue	30 (30.6%)	0	23 (35.4%)	0
Constipation	25 (25.5%)	0	18 (27.7%)	0
Stomatitis	17 (17.3%)	0	17 (26.2%)	0
Diarrhea	15 (15.3%)	0	13 (20.0%)	0
Neutropenia	12 (12.2%)	10 (10.2%)	10 (15.4%)	4 (6.2%)
Thrombocytopenia	11 (11.2%)	6 (6.1%)	10 (15.4%)	4 (6.2%)
Vomiting	8 (8.2%)	0	6 (9.2%)	0
Peripheral neuropathy	7 (7.1%)	0	6 (9.2%)	0
Liver dysfunction	7 (7.1%)	0	6 (9.2%)	0
Hypothyroidism	7 (7.1%)	0	6 (9.2%)	0
Venous thrombosis	2 (2.0%)	2 (2.0%)	2 (3.1%)	2 (3.1%)
Dizziness	2 (2.0%)	0	2 (3.1%)	0
Cough	1 (1.0%)	0	0	0	0.596

* IC induction chemotherapy
#: the p value indicated the difference of the events of grade 3–4 between the two groups

ISSN: 1471-2407